Publication | Open Access
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial
51
Citations
13
References
2020
Year
MedicineCancer ManagementGynecologyRecurrent Ovarian CancerPharmacotherapyLong-term SafetyNiraparib Versus PlaceboCancer TreatmentOncologyGynecology OncologyOvarian Cancer
| Year | Citations | |
|---|---|---|
Page 1
Page 1